世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000031713

アメリカの癌診断市場セグメンテーション分析 ― 癌遺伝子、生化学マーカー、リンホカイン、GF、CSF、ホルモン、免疫組織化学的染色 ― 競合分析、新興技術、最新機器、成長機会

VPGMarketResearch

US Cancer Diagnostics Market Segmentation Analysis: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Competitive Analysis, Emerging Technologies, Latest Instrumentation, Growth Opportunities

発刊日 2022/03/22

言語英語

体裁PDF/DataPack

ライセンス/価格

0000031713

Local PDF
Global PDF
DataPack

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。電子媒体での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

本レポートは、国、セクション、および市場セグメント別に購入可能であり、必要とする特定情報や予算に応じて特注できます。

本レポートは、今後5年間の世界の癌診断市場で出現する主なビジネスチャンスの調査に基づいています。ヨーロッパ市場の動向を明らかにし、現在および新しいアッセイを総括し、新しい診断技術の潜在的な用途を分析します。また、主要な腫瘍マーカーの売上高を国および市場セグメント別に予測し、大手企業と潜在的な市場参入企業の概要や具体的なビジネスチャンスを特定します。

論理的根拠

癌診断市場は、研究者が主要診断および治療において技術的躍進を遂げ、新たな特定抗原を発見し、疾患の遺伝子基盤の秘密を解き明かしているため、激増寸前です。今後5年間、世界の癌診断市場は、刺激的、ダイナミック、かつ急速に拡大する分野となる見込みです。技術的躍進が予期されていることにより、遺伝性素因の決定、特定腫瘍の発見、癌治療に対する生物学的反応のモニタリングのための莫大なビジネスチャンスをもたらされるでしょう。老齢人口の増加は、腫瘍アッセイに対する需要を増加させ、世界中で急速な市場拡大が進むでしょう。

調査範囲

  • アメリカ市場の概要
    ➣ 5年検査数および売上予測
    ➣ 市場力学、構造、規模、成長、主要企業など、市場セグメントの包括的分析
    ➣ 癌診断検査を実施しているラボの推定数
    ➣ アメリカにおける癌統計、病因、最近の開発
  • ビジネスチャンスおよび戦略的提案
    ➣ 今後5年間の潜在的に重要な市場アピールとともに、特定の新製品開発の機会
    ➣ 新製品のデザイン基準
    ➣ 選択すべき市場浸透戦略
    ➣ 潜在的な市場参入障壁やリスク
  • 200超の既存および新規癌診断検査
    ➣ 癌遺伝子
    ➣ 生化学マーカー
    ➣ 成長因子
    ➣ コロニー刺激因子
    ➣ ホルモン
    ➣ 免疫組織化学的染色
    ➣ リンホカイン
  • 企業シェア、売上、および検査件数の予測
    ➣ 個々の検査別の主要癌診断製品企業の売上および市場シェア
    ➣ 以下のセグメント別主要な腫瘍マーカーの5年検査件数および売上予測
      ◇ 病院
      ◇ 商業/民間ラボ
      ◇ 診療所/グループ診療
      ◇ 癌クリニック
      ◇ 外来診療センター
  • 機器のレビュー
    ➣ 動作特性、特徴や販売価格など、癌検査に使われている主な分子診断および免疫診断アナライザーの分析
  • 技術評価
    ➣ 癌診断検査における最新技術の評価と応用の可能性
    ➣ 競合/補足技術の総括
    ➣ 新たな癌診断検査や発見技術を開発している企業、大学、研究センターのリスト
  • 競合戦略
    ➣ 売上、製品ポートフォリオ、マーケティング戦略、協力協定、および新製品開発など、革新的癌診断技術や製品を開発している主要企業や新規参入企業の戦略評価

レポート詳細

目次

Table of Contents

I. Introduction

II. Worldwide Market Overview

III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

IV. Design Criteria for Decentralized Testing Products

V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

VI. Potential Market Entry Barriers and Risks
A. Market Maturity B. Cost Containment C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
 1. Breast Cancer
 2. Lung Cancer
 3. Colon and Rectum Cancer
 4. Prostate Cancer
 5. Stomach Cancer
 6. Leukemia
 7. Lymphoma
 8. Oral Cancer
 9. Skin Cancer
 10. Uterine Cancer
 11. Ovarian Cancer
 12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
 1. Introduction
 2. Tumor Marker Classification
 3. ACTH
 4. Alpha-Fetoprotein (AFP)
 5. Beta-2 Microglobulin
 6. CA 15-3/27.29
 7. CA 19-9
 8. CA-125
 9. Calcitonin
 10. Carcinoembrionic Antigen (CEA)
 11. Estrogen and Progesterone Receptors
 12. Ferritin
 13. Gastrin
 14. Human Chorionic Gonadotropin (HCG)
 15. Insulin
 16. NSE
 17. Occult Blood
 18. PAP Smear/HPV
 19. Prostatic Acid Phosphatase (PAP)
 20. Prostate-Specific Antigen (PSA)
 21. Squamous Cell Carcinoma Antigen (SCC)
 22. T and B Lymphocytes
 23. TdT
 24. Thyroglobulin
 25. Tissue Polypeptide Antigen (TPA)
 26. Biochemical Tumor Markers
 27. Oncogenes
   - Abl/abl-bcr
   - AIB1
   - BCL-2
   - BRCA1
   - CD44
   - C-fos
   - C-myb
   - C-myc
   - CYP-17
   - Erb-B
   - HPC1
   - N-myc
   - P40
   - P51
   - P53
   - PIK3CA
   - PTI-1
   - Ras
   - Reg
   - Sis
   - Src and others
 28. Polypeptide Growth Factors
   - Basic Fibroblast Growth Factor
   - Beta-TGF
   - Cachectin (TNT)
   - Calmodulin
   - ECFR
   - Nerve Growth Factor (NGF)
   - Epidermal Growth Factor (EGF)
   - Ornithine Decarboxylase
   - Transferrin
   - Transforming Growth Factor-Alpha
 29. Ectopic Hormones
 30. Colony Stimulating Factors
 31. Lymphokines
   - Alpha-Interferon
   - B Cell Growth Factors
   - B Cell Growth Factor (BCGF)
   - Gamma-Interferon
   - Interleukin-1 (IL-1)
   - Macrophage Activating Factor
 32. Immunohistochemical Stains
 33. Emerging Tumor Markers
   - N-Acetylglucosamine
   - Actin
   - Alpha-Actin
   - Antineuronal Antibodies
   - 7B2
   - B72.3
   - Bax
   - BCD-F9
   - BLCA-4
   - Blood Group Antigens A,B,H
   - CA 50
   - CA 72-4/TAG-72
   - CA 195
   - CA-242
   - CA-549
   - CAM 26
   - CAR-3
   - Cathepsin-D
   - Chromogranin A and B
   - Cluster 1 Antigen
   - Cluster-5/5A Antigen
   - CTA
   - CU18
   - DR-70
   - DU-PAN-2
   - Endometrial Bleeding Associated Factor
   - Endostatin
   - Epithelial Membrane Antigen
   - Feulgen Hydrolysis
   - Fibronectin
   - FSH
   - (1->3)-L-fucosyltransferase
   - Gastrin-Releasing Peptide (GRP)
   - GDCFP-15
   - Glucagon
   - Glycoamines
   - H23
   - Her-2
   - Human Carcinoma Antigen
   - HPA
   - HSP27
   - Intermediate Filaments
   - Cytokeratins/CK18/Cyfra 21-1
   - Desmin
   - Gliofibrillary Acid Protein
   - Neurofilaments
   - Vimentin
   - KA 93
   - Kinases
   - KP16D3
   - LAI
   - Leukocyte Common Antigen
   - Lewis Antigens
   - Lysophosphatidic Acid (LPA)
   - Ma 695/Ma 552
   - MABDF3
   - MAG
   - ME1
   - Minactivin
   - MN/CA9
   - MSA
   - Mucin Cancer Antigen (MCA)
   - Multiple Tumor Suppressor 1
   - Myosin
   - NEA-130
   - NMP22
   - OA-519
   - Opioid Peptides
   - P-glycoprotein
   - Pancreatic Oncofetal Antigen (POA)
   - Placental Lactogen
   - PR92
   - Proliferative Index, Ki-67
   - Px
   - RB Inactivation/Deletion
   - Ret
   - SCCL 175
   - Selectin
   - Sialic Acid
   - Sialyl SSEA-1/SLX
   - SN10
   - Somatostatin
   - TA-90
   - TABA
   - Tachykinin
   - TAG 12
   - TPS
   - Troponin
   - Tubulin
   - VCAM
   - VEGF
   - Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
 1. Monoclonal and Polyclonal Antibodies
 2. Immunoassays
 3. Molecular Diagnostics
 4. Chromosome Analysis
  a. Chronic Myelogenous Leukemia (CML)
  b. Acute Myeloid Leukemia (AML)
  c. Acute Lymphoblastic Leukemia (ALL)
  d. Malignant Lymphomas Lymphoid Malignancies
  e. Chronic Lymphocytic Leukemia (CLL)
  f. Solid Cancers
  g. Chromosomal Translocation and Oncogenes
 5. Artificial Intelligence
 6. Flow Cytometry
 7. Two Dimensional Gel Electrophoresis (2-DGE)
 8. Biosensors
 9. Competing/Complementing Technologies
E. Personal Testing

VIII. Country Analysis
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Dynamics, Trends, Size and Growth
   - Volume Forecasts by Test and Market Segment
   - Sales Forecasts by Test and Market Segment
   - Major Supplier Sales and Market Shares

IX. Competitive Profiles
The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:
   - Abbott
   - Affymetrix
   - Beckman Coulter/Danaher
   - Becton Dickinson
   - bioMerieux
   - Bio-Rad
   - Cepheid
   - DiaSorin
   - Eiken Chemical
   - Elitech Group
   - Enzo Biochem
   - Fujirebio
   - Grifols
   - Hologic
   - Leica Biosystems
   - Ortho-Clinical Diagnostics
   - PerkinElmer
   - Qiagen
   - Roche
   - Siemens Healthineers
   - Takara Bio
   - Thermo Fisher
   - Wako and others.

List of Tables
Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests
Major Companies Developing or Marketing
HCG Tests
Major Companies Developing or Marketing
Insulin Tests
Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: U.S., Total Tumor
Marker Test Volume and Sales Forecast by Market Segment
U.S., Laboratories Performing Tumor
Marker Tests by Market Segment
U.S., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.S., Commercial/Private Laboratories
Performing Tumor Marker Tests by Annual Test Volume
U.S., Physician Office Laboratories
Performing Tumor Marker Tests by Practice Size
U.S., Total Tumor Marker Test Volume
Forecast by Market Segment
U.S., All Market Segments Major
Tumor Marker Test Volume Forecast
U.S., Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
U.S., Physician Offices/Group Practices
Major Tumor Marker Test Volume Forecast
U.S., Cancer Clinics Major Tumor
Marker Test Volume Forecast by Test
U.S., Total Tumor Marker Sales
Forecast by Market Segment
U.S., All Market Segment Major Tumor
Marker Sales Forecast by Test
U.S., Hospital Laboratories Major Tumor
Marker Sales Forecast by Test
U.S., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by Test
U.S., Physician Offices/Group Practices
Major Tumor Marker Sales Forecast by Test
U.S., Cancer Clinics Major Tumor
Marker Sales Forecast by Test
U.S., Total Tumor Marker Sales by Major Supplier
U.S., ACTH Testing Market Diagnostics
Sales by Major Supplier
U.S., AFP Testing Market Diagnostics
Sales by Major Supplier
U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
U.S., CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier
U.S., CA 19-9 Testing Market Diagnostics
Sales by Major Supplier
U.S., CA 125 Testing Market Diagnostics
Sales by Major Supplier
U.S., CEA Testing Market Diagnostics
Sales by Major Supplier
U.S., Ferritin Testing Market
Diagnostics Sales by Major Supplier
U.S., HCG Testing Market
Diagnostics Sales by Major Supplier
U.S., Insulin Testing Market
Diagnostics Sales by Major Supplier
U.S., Parathyroid Hormone Testing Market
Diagnostics Sales by Major Supplier
U.S., PSA Testing Market Diagnostics
Sales by Major Supplier

この商品のレポートナンバー

0000031713

TOP